Can a 16-Week Intensive Program Put Type 2 Diabetes Into Remission?
An intensive 16-week program with insulin/liraglutide combination delayed diabetes relapse but did not sustain remission after drugs were stopped.
Quick Facts
What This Study Found
During the 16-week intervention, participants achieved significantly lower HbA1c (40 vs 51 mmol/mol, p < 0.0001) and lost more weight (3.3% vs 1.9%, p = 0.02) compared to controls.
After stopping all glucose-lowering drugs, there was a 37% lower hazard of diabetes relapse in the intervention group (HR 0.63, 95% CI 0.45-0.88, p = 0.007). However, this benefit did not last. At 12 weeks post-intervention, remission rates were 17.7% vs 12.5% (not significant). At 52 weeks, they were 6.3% vs 3.8% (not significant).
The key takeaway: intensive metabolic intervention delayed relapse but could not sustain remission once drugs were stopped.
Key Numbers
- 159 participants randomized (79 intervention, 80 control)
- Age: 57 ± 10 years
- Diabetes duration: 2.6 ± 1.5 years
- BMI: 33.5 ± 6.5 kg/m²
- Baseline HbA1c: 53 ± 7 mmol/mol
- Post-intervention HbA1c: 40 vs 51 mmol/mol (p < 0.0001)
- Weight loss: 3.3% vs 1.9% (p = 0.02)
- Hazard of relapse: HR 0.63 (95% CI 0.45-0.88, p = 0.007)
- 52-week remission: 6.3% vs 3.8% (not significant)
How They Did This
This was a multicenter, open-label randomized controlled trial. 159 insulin-naive participants within 5 years of type 2 diabetes diagnosis were randomized to a 16-week intensive intervention (dietary coaching, exercise coaching, diabetes management coaching, metformin, and fixed-ratio insulin degludec/liraglutide) or standard care. After the intervention period, all glucose-lowering drugs were stopped, and patients were followed for one year for diabetes relapse and sustained remission.
Why This Research Matters
Type 2 diabetes remission is a hot topic. Some studies show intensive weight loss can put diabetes into remission. This trial tested whether adding a powerful GLP-1/insulin combination to lifestyle changes could boost remission rates. The disappointing result, where remission did not last, suggests that more than 16 weeks of intervention may be needed, or that the weight loss achieved (3.3%) was too modest.
The Bigger Picture
Diabetes remission studies show that intensive weight loss is key. This trial's modest 3.3% weight loss likely explains why remission was not sustained — other successful remission programs achieved 10–15% weight loss.
What This Study Doesn't Tell Us
The trial was open-label, meaning both patients and doctors knew who received the intervention, which could bias results. The weight loss achieved (3.3%) was modest compared to trials that successfully achieved remission. The 16-week intervention period may have been too short. The sample size (159) limited power to detect small remission rate differences. The insulin degludec/liraglutide combination may have suppressed HbA1c pharmacologically without changing the underlying disease.
Questions This Raises
- ?Would more aggressive weight loss targets have changed the outcome?
- ?Is 16 weeks long enough for lasting metabolic change?
- ?Would newer drugs like tirzepatide perform better in this protocol?
Trust & Context
- Key Stat:
- 6.3% remission at 1 year Only about 1 in 16 intervention patients maintained diabetes remission a year after stopping all medications
- Evidence Grade:
- Rated strong: multicenter randomized controlled trial with clear endpoints and follow-up, even though the result was negative for sustained remission.
- Study Age:
- Published in 2024. Adds to the growing body of diabetes remission research, including the influential DiRECT trial.
- Original Title:
- Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
- Published In:
- Diabetes, obesity & metabolism, 26(12), 5600-5608 (2024)
- Authors:
- Punthakee, Zubin, Hall, Stephanie, McInnes, Natalia, Sherifali, Diana, Tsiplova, Kate, Kirabo, Faith R, Ransom, Thomas P P, Harris, Stewart B, Lochnan, Heather A, Sigal, Ronald J, Ghosh, Mahua, Spaic, Tamara, Gerstein, Hertzel C
- Database ID:
- RPEP-09094
Evidence Hierarchy
Frequently Asked Questions
Can you put diabetes into remission with drugs?
This trial found drugs alone weren't enough. The intervention improved blood sugar during treatment, but remission rarely lasted after drugs were stopped.
How much weight loss is needed for diabetes remission?
Successful remission studies typically achieved 10–15% body weight loss. This trial achieved only 3.3%, which was likely insufficient for lasting metabolic change.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09094APA
Punthakee, Zubin; Hall, Stephanie; McInnes, Natalia; Sherifali, Diana; Tsiplova, Kate; Kirabo, Faith R; Ransom, Thomas P P; Harris, Stewart B; Lochnan, Heather A; Sigal, Ronald J; Ghosh, Mahua; Spaic, Tamara; Gerstein, Hertzel C. (2024). Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.. Diabetes, obesity & metabolism, 26(12), 5600-5608. https://doi.org/10.1111/dom.15926
MLA
Punthakee, Zubin, et al. "Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.." Diabetes, 2024. https://doi.org/10.1111/dom.15926
RethinkPeptides
RethinkPeptides Research Database. "Evaluating remission of type 2 diabetes using a metabolic in..." RPEP-09094. Retrieved from https://rethinkpeptides.com/research/punthakee-2024-evaluating-remission-of-type
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.